An immunosuppressive drug could delay the onset of neurodegenerative diseases

October 15, 2012

Rapamycin, a drug used to prevent rejection in transplants, could delay the onset of neurodegenerative diseases such as Alzheimer's and Parkinson's. This is the main conclusion of a study published in the Nature in which has collaborated the researcher Isidro Ferrer, head of the group of Neuropathology at the Bellvitge Biomedical Research Institute (IDIBELL) and the Bellvitge University Hospital and Full Professor of Pathological Anatomy at the University of Barcelona. The research was led by researchers from the International School for Advanced Studies (SISSA) in Trieste (Italy).

The collaboration of the research group led by Dr. Ferrer with SISSA researchers began five years ago when they observed that Parkinson's patients showed a deficit in UCHL1 protein. At that time, researchers didn't know what mechanism produced this deficit. To discover it a European project was launched. It was coordinated by the Italian researchers and participated by other European research groups, including the group led by Dr. Ferrer. The project, called Dopaminet, focused on how dopaminergic neurons ( whose neurotransmitter is dopamine) are involved in Parkinson's disease.

Contrary to most common hypothesis that a encodes a protein through a molecule, the researchers found that it also works in reverse. They found a balance between the protein and its mirror protein, which is configured in reverse, and they are mutually controlled. If the protein mirror is located in the nucleus of the cell, it does not interact with the protein, while if it is in the cytoplasm, then both of them interact.

In the case of Parkinson's disease the protein UCHL1 appears reduced and also its mirror protein is localized in the nucleus, and in the cytoplasm. Thus, the researchers sought a method to extract the mirror protein from the nucleus and made it interact with the original UCHL1 protein. The authors found that rapamycin was able to extract them from the nucleus. The drug allows the two proteins, the UCHL1 and its mirror, hold together in the cytoplasm, which would correct the mistakes that occur in Parkinson's disease.

This in vitro research has allowed describing a new unknown mechanism. It is necessary that the UCHL1 mirror protein should accumulate in the nucleus and escape from the and join the UCLH1 protein. The combination of both makes the system work.

"The rapamycin can not cure Parkinson's disease, but it may delay the onset of such as Alzheimer's and Parkinson's itself. Rapamycin can protect and delay the beginning of these diseases. It can complete the treatment, but it should be combined with other existing treatments", explains Isidro Ferrer.

Anyway, it is still far its application in patients. The next step is to validate these results in animal models and study the effects of rapamycin in combination with other drugs.

Explore further: Brain variants of protein associated with Huntington's and other neurodegenerative diseases identified

More information: Claudia Carrieri, Laura Cimatti, Marta Biagioli, Anne Beugnet, Silvia Zucchelli, Stefania Fedele, Elisa Pesce,Isidre Ferrer, Licio Collavin, Claudio Santoro, Alistair R. R. Forrest, Piero Carninci, Stefano Biffo, Elia Stupka & Stefano Gustincich. Long non-coding antisense RNA controls Uchl1 translation through an embedded SINEB2 repeat. Nature. DOI: 10.1038/nature11508

Related Stories

Brain variants of protein associated with Huntington's and other neurodegenerative diseases identified

July 23, 2012
(Medical Xpress) -- A protein essential for metabolism and recently associated with neurodegenerative diseases also occurs in several brain-specific forms. This discovery emerged in the course of a research project funded ...

Finding brings scientists one step closer to Parkinson's drug

June 27, 2012
Van Andel Institute announces that researchers at Lund University in Sweden have published a study detailing how Parkinson's disease spreads through the brain. Experiments in rat models uncover a process previously used to ...

How Parkinson's disease starts and spreads

April 16, 2012
Injection of a small amount of clumped protein triggers a cascade of events leading to a Parkinson's-like disease in mice, according to an article published online this week in the Journal of Experimental Medicine.

Recommended for you

Faulty cell signaling derails cerebral cortex development, could it lead to autism?

September 20, 2017
As the embryonic brain develops, an incredibly complex cascade of cellular events occur, starting with progenitors - the originating cells that generate neurons and spur proper cortex development. If this cascade malfunctions ...

Research redefines proteins' role in the development of spinal sensory cells

September 19, 2017
A recent study led by Samantha Butler at the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA has overturned a common belief about how a certain class of proteins in the spinal cord regulate ...

The brain at work: Spotting half-hidden objects

September 19, 2017
How does a driver's brain realize that a stop sign is behind a bush when only a red edge is showing? Or how can a monkey suspect that the yellow sliver in the leaves is a round piece of fruit?

Team discovers how to train damaging inflammatory cells to promote repair after stroke

September 19, 2017
White blood cells called neutrophils are like soldiers in your body that form in the bone marrow and at the first sign of microbial attack, head for the site of injury just as fast as they can to neutralize invading bacteria ...

Epileptic seizures show long-distance effects

September 19, 2017
The area in which an epileptic seizure starts in the brain, may be small but it reaches other parts of the brain at distances of over ten centimeters. That distant activity, in turn, influences the epileptic core, according ...

Learning and unlearning to fear: The two faces of noradrenaline

September 18, 2017
Emotional learning can create strong memories and powerful emotional responses, but flexible behavior demands that these responses be inhibited when they are no longer appropriate. Scientists at the RIKEN Brain Science Institute ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.